• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 8, 2015

View Archived Issues

Nucynta nuisance or bright Horizon? Rebuff by Depomed of $3B buyout; game not over

Another hostile takeover bid in the industry – this time by Horizon Pharma plc to grab Depomed Inc. for $29.25 per share in an all-stock, tax-free deal – set Wall Street buzzing, as Horizon offered a 42 percent premium over Monday's closing price of Depomed to make a deal valued at about $3 billion. Read More

Bavarian Nordic's smallpox vaccine wins $133M U.S. contract

DUBLIN – Bavarian Nordic A/S picked up a new $133 million supply contract for its Imvamune smallpox vaccine from the U.S. government, evidence that its infectious disease business continues to prosper, even if cancer immunotherapy is now the company's main value driver. Read More

Report calls for measures to preserve India's brand in global pharma market

NEW DELHI – A new report to the government of India suggests the adoption of a slew of measures to help domestic pharma firms, especially small firms that form the bulk of the industry, better understand the global regulatory landscape and meet compliance standards in advanced countries. Read More

Thalidomide derivative key to new antileukemic therapies, study shows

HONG KONG – The mechanism by which the thalidomide derivative lenalidomide treats a type of myelodysplastic syndrome (MDS) has been elucidated, reported in the July 1, 2015, edition of Nature, could aid the development of new therapies for leukemias and other malignancies. Read More

As drug shortages decline, FDA finalizes its reporting rule

Properly reporting and mitigating a potential drug shortage could cost drugmakers up to $40.5 million, the FDA said in a new rule finalizing amendments to its drug shortage reporting requirements. Read More

'Very complex issue': Australian tax inquiry calls big pharma to floor

HONG KONG – A series of enquiries in Australia into tax payments by multinational pharmaceutical companies is likely to have little impact on their operations, particularly outside the country, despite the concern of authorities there. Read More

Financings

Oasmia Pharmaceutical AB, of Uppsala, Sweden, said it filed a registration statement on Form F-1/A with the SEC in connection with a proposed public offering of ordinary stock and a listing on Nasdaq under the ticker OASM. Read More

Other news to note

Ignyta Inc., of San Diego, formed a clinical collaboration with the University of California, San Francisco (UCSF), which will study entrectinib in a multicenter, open-label, proof-of-concept trial in patients with metastatic melanoma that is positive for activating alterations in the tyrosine kinase receptors NTRK1/2/3 (encoding TrkA/TrkB/TrkC) or ROS1. Read More

Stock movers

Read More

In the clinic

Molecular Partners AG, of Zurich-Schlieren, Switzerland, said its partner Allergan plc, of Dublin, has initiated phase III trials with abicipar pegol for the treatment of wet age-related macular degeneration. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • AI-generated illustration of CAR T cells

    Researchers arm CAR T cells to fight solid tumors

    BioWorld
    Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
  • Digital lungs illustration

    Bioversys, Shionogi in CHF529M lung infection collaboration

    BioWorld Science
    Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...
  • Medtronic Vitalflow ECMO

    Medtronic receives CE mark for its Vitalflow ECMO system

    BioWorld MedTech
    Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe